Business Confidence Reaches Its Strongest Level in Years
Danish businesses have become more optimistic about economic conditions, with confidence reaching its highest level in around four years despite continued concerns surrounding the country’s important pharmaceutical industry.
The improvement highlights the resilience of Denmark’s broader economy at a time when its largest pharmaceutical company, Novo Nordisk, faces increasing competition and uncertainty in the global market for weight-loss and diabetes drugs.
Business confidence across Denmark’s major sectors, including manufacturing, construction, retail and services, strengthened significantly in recent months. The country’s composite business confidence indicator rose to 105.4 in July from 101.0 in June, while manufacturing confidence also improved sharply.
The figures suggest that optimism is spreading beyond the pharmaceutical sector, helping offset concerns about one of Denmark’s most important corporate success stories.
Denmark’s Economy Looks Beyond Pharmaceuticals
Denmark’s economy has become closely associated with its powerful pharmaceutical industry.
Novo Nordisk, in particular, has played a major role in the country’s recent economic growth because of the enormous global success of diabetes and obesity treatments such as Ozempic and Wegovy.
However, the company’s recent difficulties have raised concerns about whether Denmark can continue relying heavily on pharmaceutical exports for economic momentum.
Novo Nordisk faces intense competition from US rival Eli Lilly, particularly in the rapidly growing obesity-drug market. Investors have also expressed concerns about the company’s next generation of treatments and its ability to maintain its leadership position.
Despite these challenges, the latest business-confidence figures suggest that other parts of Denmark’s economy are becoming more optimistic.
That could reduce fears that weakness in the pharmaceutical sector will automatically translate into a broader economic slowdown.
Manufacturing Confidence Shows a Strong Recovery
Manufacturing was one of the strongest areas in the latest confidence data.
Denmark’s manufacturing confidence indicator increased to 99.2 in July from 90.7 in June, representing a significant improvement in sentiment.
Production expectations strengthened, while employment expectations became less negative.
The improvement is particularly important because manufacturers face several challenges, including changes in global trade, energy costs and uncertainty surrounding international demand.
A recovery in confidence suggests that businesses may be expecting stronger production and sales conditions in the months ahead.
For Denmark, a healthier manufacturing sector could also help diversify economic growth beyond pharmaceuticals.
Services and Retail Add to the Optimism
The improvement was not limited to factories.
Confidence in Denmark’s service sector increased to 107.3, while retail confidence moved into positive territory at 106.3, according to the latest data.
The service sector is particularly important because it represents a large part of the modern Danish economy.
Greater confidence among service companies can indicate expectations of stronger consumer spending, business investment and overall economic activity.
Retail optimism also provides an important signal about household demand.
If consumers remain willing to spend, businesses may become more confident about hiring, expanding operations and investing in future growth.
Together, the improvement across manufacturing, services and retail suggests that Denmark’s optimism is relatively broad-based.
Novo Nordisk Remains a Major Source of Concern
Despite the encouraging confidence figures, Denmark cannot completely escape the problems affecting its pharmaceutical industry.
Novo Nordisk remains one of the country’s largest and most internationally important companies.
The company’s growth helped transform Denmark into a major beneficiary of the global demand for obesity and diabetes medicines.
But the situation has become more complicated.
Novo recently raised its 2026 outlook after reporting stronger-than-expected second-quarter results. Adjusted sales increased 7% at constant exchange rates, while adjusted operating profit rose 11%.
However, investors remained cautious.
The company’s updated outlook did not fully reassure the market because analysts continue to focus on competition, the performance of its Wegovy pill and setbacks involving next-generation obesity treatments.
This has created what could be described as a pharma gloom hanging over an otherwise increasingly confident business environment.
Competition From Eli Lilly Changes the Industry
The obesity-drug market remains one of the fastest-growing areas of the global pharmaceutical industry.
Analysts expect the market to eventually be worth more than $100 billion annually, making it a major strategic battleground for companies such as Novo Nordisk and Eli Lilly.
Novo Nordisk was one of the companies that helped create the modern market for GLP-1 weight-loss drugs.
However, Eli Lilly has gained significant momentum with its competing treatments, putting pressure on Novo’s market position.
Investors are now watching closely to see whether Novo can strengthen its research pipeline and develop enough new products to remain competitive.
The company’s management has responded by focusing on faster research and development and potential acquisitions that could strengthen its future portfolio.
For Denmark, the outcome matters far beyond the company’s share price.
A prolonged slowdown at Novo Nordisk could affect exports, investment, employment and tax revenues.
Denmark’s Broader Economy Shows Resilience
The latest confidence figures therefore carry an important message.
Denmark’s economy is not entirely dependent on one pharmaceutical company.
While Novo Nordisk remains enormously important, the improvement in confidence across services, manufacturing and retail suggests that other businesses are also expecting better conditions.
The composite business-confidence indicator’s rise from 101.0 to 105.4 indicates a significant improvement across the private sector.
Construction confidence, meanwhile, remained broadly stable around 101.0, suggesting that optimism is not limited to only one or two industries.
This broader improvement could help Denmark absorb potential weakness in pharmaceuticals.
A diversified economy is generally better positioned to handle problems affecting an individual industry.
Global Trade Remains a Risk
Despite the positive sentiment, Danish companies still face significant external risks.
Denmark is a relatively small economy with a strong dependence on international trade.
Its businesses are therefore sensitive to changes in global demand, trade policies, currency movements and geopolitical developments.
A slowdown in Europe, the United States or other major export markets could affect Danish manufacturers and service providers.
Trade tensions could also create additional costs for companies that depend on international supply chains.
This means the current improvement in confidence does not guarantee continued economic growth.
Businesses can become optimistic about future conditions, only to change their outlook if global economic conditions deteriorate.
Consumer Demand Could Support Growth
One reason for improving business sentiment may be the continued strength of domestic economic activity.
Retail confidence turning positive suggests that businesses expect consumers to remain active.
Strong consumer spending can support a wide range of industries, including retail, hospitality, transportation and professional services.
It can also encourage companies to invest more in their operations.
If businesses expect demand to increase, they may expand production, hire additional workers and purchase new equipment.
That can create a positive cycle in which stronger consumer activity supports business confidence and greater business activity supports employment.
However, this cycle depends on inflation, interest rates and household finances remaining relatively stable.
Interest Rates Will Remain Important
Denmark’s economy is closely connected to developments in the broader European financial system.
Changes in interest rates can affect borrowing costs for businesses and households, influencing investment and spending decisions.
Lower or stable borrowing costs can encourage companies to invest, while higher rates can reduce demand for housing, equipment and other major purchases.
Businesses will therefore continue monitoring monetary-policy decisions and inflation trends.
If inflation remains controlled, financial conditions may provide greater support for economic growth.
But a new rise in energy prices or other external inflation pressures could change the outlook.
Business Confidence Is Not the Same as Economic Growth
It is important to remember that confidence surveys measure expectations rather than guaranteed outcomes.
A company may report that it expects stronger business conditions, but those expectations can change quickly.
Nevertheless, confidence is an important economic indicator.
When businesses become more optimistic, they may be more likely to:
- Increase investment
- Expand production
- Hire additional workers
- Purchase equipment
- Increase inventories
- Launch new products
- Enter new markets
These decisions can eventually contribute to stronger economic growth.
The recent improvement across multiple sectors therefore provides an encouraging signal for Denmark’s economy.
Novo Nordisk Still Has Significant Strength
Although the pharmaceutical company faces increasing challenges, its situation is not entirely negative.
Novo Nordisk continues to generate substantial revenue and profit, and demand for obesity treatments remains strong.
The company reported second-quarter adjusted operating profit of approximately 33.4 billion Danish kroner, while its updated 2026 guidance was stronger than its previous forecast.
Its Wegovy pill has also shown significant early demand in the United States, with weekly prescriptions exceeding 265,000 for the week ending July 17.
The concern is therefore not that Novo Nordisk is suddenly becoming a weak company.
Instead, investors are questioning whether it can continue growing at the extraordinary pace that previously made it one of Europe’s most valuable companies.
That distinction is important for Denmark’s economic outlook.
Even slower growth at Novo could still leave the company as a major contributor to the country’s economy.
The Pharma Industry Could Become More Competitive
The current challenges may also encourage Novo Nordisk and other pharmaceutical companies to become more aggressive.
Greater competition can accelerate research, investment and product development.
Novo’s management has already indicated that it wants to move faster in research and development and strengthen its pipeline through additional opportunities.
If the company successfully develops new treatments, Denmark’s pharmaceutical industry could regain momentum.
However, the sector will likely remain volatile as competition intensifies.
Drug development is expensive and uncertain.
A successful clinical trial can create billions of dollars in potential value, while disappointing results can significantly affect investor confidence.
Denmark Faces a More Balanced Economic Picture
The contrast between strong business confidence and pharmaceutical uncertainty creates a more balanced picture of Denmark’s economy.
On one side, companies across manufacturing, services and retail are becoming increasingly optimistic.
On the other, one of Denmark’s most important companies faces growing competition and questions about its future growth.
The encouraging part is that optimism appears to extend across several industries.
The composite confidence index and sector-specific improvements suggest that the broader business community is not experiencing the same level of pessimism affecting pharmaceutical investors.
This could give Denmark greater economic stability.
If other industries continue expanding, they may help offset some of the risks associated with a slowdown in pharmaceutical growth.
Looking Ahead
Denmark’s latest business-confidence figures suggest that the country’s private sector is becoming increasingly optimistic despite the uncertainty surrounding its pharmaceutical industry.
Manufacturing confidence improved sharply, while services and retail also strengthened. The composite business-confidence indicator rose to 105.4 in July, compared with 101.0 in June, reflecting a broad improvement across the economy.
The biggest challenge remains the future of Novo Nordisk.
The pharmaceutical giant continues to generate strong profits and demand for its products remains significant. However, competition from Eli Lilly and concerns about its next generation of obesity treatments have created uncertainty among investors.
For Denmark, the situation represents an important test.
The country has benefited enormously from the global success of Novo Nordisk, but the latest data suggests that its broader business community may be capable of supporting economic growth even if the pharmaceutical giant experiences a more difficult period.
If optimism across manufacturing, services and retail continues, Denmark could enter the coming months with a stronger and more diversified economic outlook.
The country’s business sector is therefore sending a relatively positive message: while pharmaceutical concerns remain significant, Denmark’s wider economy is showing enough confidence to look beyond the gloom surrounding one of its most important industries.
